Entero Therapeutics, Stock Probability of Future Stock Price Finishing Over 0.42
| ENTO Stock | 0.42 0.02 5.00% |
Entero |
Entero Therapeutics, Target Price Odds to finish over 0.42
The tendency of Entero Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.42 | 90 days | 0.42 | about 67.78 |
Based on a normal probability distribution, the odds of Entero Therapeutics, to move above the current price in 90 days from now is about 67.78 (This Entero Therapeutics, probability density function shows the probability of Entero Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.46 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Entero Therapeutics, will likely underperform. Additionally Entero Therapeutics, has an alpha of 0.7147, implying that it can generate a 0.71 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Entero Therapeutics, Price Density |
| Price |
Predictive Modules for Entero Therapeutics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entero Therapeutics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entero Therapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entero Therapeutics, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Entero Therapeutics, is not an exception. The market had few large corrections towards the Entero Therapeutics,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entero Therapeutics,, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entero Therapeutics, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.71 | |
β | Beta against Dow Jones | 3.46 | |
σ | Overall volatility | 0.13 | |
Ir | Information ratio | 0.07 |
Entero Therapeutics, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entero Therapeutics, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entero Therapeutics, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Entero Therapeutics, is way too risky over 90 days horizon | |
| Entero Therapeutics, has some characteristics of a very speculative penny stock | |
| Entero Therapeutics, appears to be risky and price may revert if volatility continues | |
| Entero Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| Entero Therapeutics, was previously known as First Wave BioPharma and was traded on NASDAQ Exchange under the symbol FWBI. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entero Therapeutics, generates negative cash flow from operations | |
| Entero Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth 148,925 |
Entero Therapeutics, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Entero Stock often depends not only on the future outlook of the current and potential Entero Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Entero Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 336.3 K | |
| Cash And Short Term Investments | 3.7 M |
Entero Therapeutics, Technical Analysis
Entero Therapeutics,'s future price can be derived by breaking down and analyzing its technical indicators over time. Entero Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Entero Therapeutics,. In general, you should focus on analyzing Entero Stock price patterns and their correlations with different microeconomic environments and drivers.
Entero Therapeutics, Predictive Forecast Models
Entero Therapeutics,'s time-series forecasting models is one of many Entero Therapeutics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Entero Therapeutics,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Entero Therapeutics,
Checking the ongoing alerts about Entero Therapeutics, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Entero Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Entero Therapeutics, is way too risky over 90 days horizon | |
| Entero Therapeutics, has some characteristics of a very speculative penny stock | |
| Entero Therapeutics, appears to be risky and price may revert if volatility continues | |
| Entero Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| Entero Therapeutics, was previously known as First Wave BioPharma and was traded on NASDAQ Exchange under the symbol FWBI. | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Entero Therapeutics, generates negative cash flow from operations | |
| Entero Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth 148,925 |
Check out Entero Therapeutics, Backtesting, Entero Therapeutics, Valuation, Entero Therapeutics, Correlation, Entero Therapeutics, Hype Analysis, Entero Therapeutics, Volatility, Entero Therapeutics, History as well as Entero Therapeutics, Performance. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.